MOLOGEN AG
MOLOGEN presented poster at ESMO WCGI 2015
MOLOGEN AG / Key word(s): Conference MOLOGEN presented poster at ESMO WCGI 2015 Berlin, July 6, 2015 – The biotechnology company MOLOGEN AG presented a poster on the clinical trial IMPALA with the cancer immunotherapy MGN1703 at the ESMO 17th World Congress on Gastrointestinal Cancer (WCGI) in Barcelona (July 1-4, 2015). The poster was titled “Immunomodulatory switch maintenance therapy to improve overall survival in metastatic colorectal carcinoma: The phase 3 IMPALA study” and featured information on the rationale and design of the ongoing trial. All abstracts from the ESMO 17th World Congress on Gastrointestinal Cancer are published in a supplement to the Annals of Oncology journal. For more information on the ESMO World Congress on Gastrointestinal Cancer please visit ESMO’s website www.esmo.org. About IMPALA Leading medical associations will participate: Arbeitsgemeinschaft Internistische Onkologie (AIO) in Germany, Grupo Españiol de Tratamiento de Tumores Digestivos (TTD) in Spain and Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) in France. The steering committee consists of international medical experts; among others the coordinating study investigators Prof. David Cunningham, MD, Department of Medicine and Director of Clinical Research, Royal Marsden Hospital in London, and Prof. Dirk Arnold, MD, Director of the Clinic for Medical Oncology, Klinik für Tumorbiologie, Freiburg, Germany. For more information on the trial IMPALA please visit www.clinicaltrials.gov. About MGN1703 MOLOGEN AG The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and small cell lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
2015-07-06 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News-Service |
375483 2015-07-06 |